Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide combined with bortezomib, dexamethasone, and liposomal doxorubicin for relapsed/refractory multiple myeloma
ChiCTR1900027562Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, bortezomib, dexamethasone and pegylated liposomal doxorubicin in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoints: Blood routine, Biochemistry and 1 more. Started Dec 2019; status: recruiting.
02
Drugs
tucidinostatbortezomibdexamethasonepegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900027562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027562.